CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Quarterly Report Filed: 2026-05-08

Key Insights

The filing shows Q1 2026 results for a healthcare company with dual-class share structure (Class A and Class B common stock), indicating potential governance complexities and different voting rights among shareholders.
The document contains extensive fair value measurement disclosures across multiple hierarchy levels (Level 1, 2, and 3), suggesting the company maintains significant investment portfolios including private equity investments that require complex valuation methodologies.
The presence of related party transactions with Medical Records Exchange LLC indicates ongoing business relationships that require careful monitoring for potential conflicts of interest and fair dealing considerations.
The filing includes treasury stock activity and restricted stock unit (RSU) compensation across multiple periods, suggesting active share repurchase programs and equity-based employee compensation strategies.

Current Report Filed: 2026-05-06

Key Insights

Company announced Q1 2026 financial results on May 6, 2026, indicating routine quarterly earnings disclosure with no material adverse events mentioned in the filing.
Leadership note: Clay Thornton is identified as Interim Chief Financial Officer, suggesting potential CFO transition or vacancy that investors should monitor for stability concerns.
Company operates as remote-first with no physical headquarters, directing stockholder communications to Delaware agent for service of process, which is an operational structure choice rather than a material business development.

Insider Trading Filed: 2026-04-21

Key Insights

Brady Priest, CEO of Clover Care Services, disposed of 36,113 shares through automatic tax withholding on vesting of RSUs at $2.19 per share, representing a routine equity compensation event rather than discretionary selling.
This transaction reflects the continued quarterly vesting of RSUs granted in July 2022, with the final vesting installment scheduled for July 18, 2026, indicating the executive's equity compensation package is nearing completion.
Post-transaction beneficial ownership stands at 2,138,261 shares, demonstrating substantial direct ownership stake by the reporting person in CLOV, which aligns insider interests with shareholders despite the vesting-related share reduction.

Insider Trading Filed: 2026-04-16

Key Insights

The reporting person, Brady Priest, who serves as the CEO of Clover Care Services, has disposed of 15,471 shares of Clover Health Investments' Class A common stock to cover tax obligations related to the vesting of restricted stock units (RSUs).
The remaining RSUs granted to Priest on October 15, 2024, will continue to vest quarterly in equal installments of 6.25% until the final vesting date on October 15, 2028, subject to his continued service.
The transaction appears to be a routine tax-related sale and does not indicate any significant change in Priest's overall beneficial ownership of Clover Health Investments' shares, which remains at 2,174,374 shares.

Insider Trading Filed: 2026-04-16

Key Insights

The reporting person, Karen Soares, is the Chief Legal Officer of Clover Health Investments, Corp. and has been awarded restricted stock units (RSUs) that vest over time.
On April 15, 2026, Soares had 10,161 shares of Class A common stock automatically withheld to cover tax obligations due to the vesting of a portion of her RSUs.
The remaining RSUs continue to vest quarterly in equal installments until the final vesting date on October 15, 2028, subject to Soares' continued service.

Insider Trading Filed: 2026-04-16

Key Insights

The reporting person, Andrew Toy, is the Chief Executive Officer of Clover Health Investments, Corp. and appears to have disposed of 60,765 shares of Class A common stock to cover tax obligations related to the vesting of restricted stock units.
The remaining restricted stock units granted to the reporting person continue to vest quarterly in equal installments through October 2028, indicating ongoing executive retention and alignment with shareholders.
The reported transaction appears to be a routine stock sale to cover tax obligations and does not suggest any significant change in the reporting person's overall beneficial ownership position in the company.

Insider Trading Filed: 2026-04-16

Key Insights

Joseph Clay Thornton, the Interim CFO of Clover Health Investments, Corp., disposed of 4,158 shares of Class A common stock on April 15, 2026, likely to cover tax obligations related to the vesting of restricted stock units.
Thornton still holds a significant number of 1,234,526 shares of Class A common stock, indicating he maintains a substantial equity stake in the company.
The vesting schedule for Thornton's restricted stock units suggests he is incentivized to drive long-term performance, as the final tranche of RSUs is set to vest on October 15, 2028.

Insider Trading Filed: 2026-04-16

Key Insights

The reporting person, Jamie L. Reynoso, CEO of Clover Health Investments, Corp., has executed a transaction involving the disposition of 12,712 shares of Class A common stock on April 15, 2026.
The disposition of shares appears to be related to the vesting of restricted stock units (RSUs) previously granted to the reporting person, with the remaining RSUs scheduled to vest quarterly over the next two years.
The transaction is part of a planned equity compensation arrangement, suggesting the reporting person's continued commitment to the company's long-term success.

Insider Trading Filed: 2026-04-16

Key Insights

The CEO, Conrad Wai, has continued to hold a significant amount of Clover Health Investments' Class A common stock, with over 1.6 million shares held indirectly through a trust.
Wai's recent transaction involved the automatic withholding of 23,463 shares to cover tax obligations related to the vesting of restricted stock units (RSUs), indicating ongoing equity-based compensation.
The remaining RSUs continue to vest quarterly, with the final vesting date in October 2028, suggesting Wai's long-term commitment to the company.

Insider Trading Filed: 2026-04-07

Key Insights

The CEO, Jamie L. Reynoso, has sold a modest amount of Clover Health Investments shares to cover tax obligations from the vesting of restricted stock units, suggesting no major change in ownership or position.
The remaining restricted stock units will continue to vest in equal quarterly installments through January 2027, aligning the CEO's incentives with long-term shareholder value creation.
The transaction appears routine and does not indicate any significant changes or concerns regarding the CEO's confidence in the company's outlook.

Insider Trading Filed: 2026-04-03

Key Insights

Clover Health Investments' CEO Brady Priest acquired 191,261 shares of Class A common stock through a time-based restricted stock unit (RSU) award, indicating his continued commitment to the company.
The RSUs will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in 12 equal quarterly installments, aligning Priest's incentives with long-term shareholder value creation.
This transaction represents a significant insider buy, with Priest's total beneficial ownership now standing at 2,189,845 shares, suggesting his confidence in Clover Health's future prospects.

Insider Trading Filed: 2026-04-03

Key Insights

The CEO of Clover Health, Jamie L. Reynoso, has acquired 159,384 shares of Class A common stock through a time-based restricted stock unit award, indicating their continued commitment to the company.
The vesting schedule for the restricted stock units shows that 25% will vest on the first anniversary of April 1, 2026, and the remaining 75% will vest in twelve equal quarterly installments over the following three years, aligning the CEO's incentives with long-term shareholder value.
The substantial increase of 159,384 shares in the CEO's beneficial ownership, representing a 5.9% increase in their holdings, suggests their confidence in Clover Health's future performance.

Insider Trading Filed: 2026-04-03

Key Insights

Insider Andrew Toy, the CEO of Clover Health, acquired a significant number of 956,307 shares of the company's Class A common stock through a time-based restricted stock unit (RSU) award, indicating his confidence in the company's long-term growth prospects.
The reported transaction also shows that Toy disposed of 309,558 shares to cover tax obligations, which is a common practice for executives when RSUs vest.
The vesting schedule of the RSUs, with 25% vesting on the first anniversary and the remaining 75% vesting in 12 equal quarterly installments, suggests a long-term incentive structure to align Toy's interests with those of shareholders.

Insider Trading Filed: 2026-04-03

Key Insights

The reporting person, Conrad Wai, acquired 267,766 shares of Class A common stock of Clover Health Investments, Corp. through a time-based restricted stock unit award, which will vest over time.
Wai also holds an additional 1,610,482 shares of Class A common stock indirectly through a trust, indicating significant insider ownership.
The vesting schedule of the restricted stock units suggests that Wai is expected to remain in his role as CEO of Counterpart Health, a subsidiary of Clover Health, for the next several years.

Insider Trading Filed: 2026-04-03

Key Insights

Karen Soares, the Chief Legal Officer of Clover Health Investments, Corp., has been granted 382,522 shares of Class A common stock in the form of a restricted stock unit (RSU) award. This suggests the company is incentivizing its key leadership to align their interests with shareholders.
The RSUs will vest over a 4-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in quarterly installments, indicating a long-term focus on retaining and motivating Soares.
The direct ownership of 1,582,583 Class A common shares by Soares represents a significant stake in the company, potentially signaling her confidence in Clover Health's future prospects.

Current Report Filed: 2026-04-01

Key Insights

Clover Health Investments is undergoing a transition in the Chief Financial Officer role, with Peter Kuipers stepping down and Clay Thornton being appointed as the Interim CFO.
Joseph Oldakowski has been appointed as the Company's principal accounting officer, bringing extensive experience in finance and accounting roles at various healthcare organizations.
The departure of the CFO does not appear to be due to any disagreement between the Company and Mr. Kuipers, but rather a planned transition.

Insider Trading Filed: 2026-03-18

Key Insights

Insider Jamie L. Reynoso, the CEO of Clover Health, sold 5,833 shares of Class A common stock on March 18, 2026 at a weighted average price of $1.91 per share.
The sale was executed pursuant to a pre-planned 10b5-1 trading plan, indicating it was not an opportunistic transaction.
Reynoso still maintains a significant stake of 2,716,735 Class A shares, suggesting continued confidence in the company's long-term prospects.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person, Karen Soares, is the General Counsel and Secretary of Clover Health Investments, Corp., indicating her role as a key executive at the company.
Soares disposed of 4,528 shares of Class A common stock on March 15, 2026, which were automatically withheld to cover tax obligations upon the vesting of restricted stock units (RSUs).
The remaining RSUs granted to Soares on September 15, 2022, will vest quarterly in equal installments of 6.25% until the final vesting date on September 15, 2026, subject to her continued service.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person Conrad Wai, who is the CEO of Clover Health Investments, Corp., has disposed of 100,195 shares of Class A common stock by automatic withholding to cover tax obligations upon the vesting of restricted stock units.
The reporting person continues to beneficially own a significant amount of Clover Health Investments stock, with 925,611 shares held directly and an additional 1,610,482 shares held indirectly through a trust.
The insider transaction appears to be a routine tax-related sale and not an indication of significant selling pressure or concerns about the company's prospects.

Insider Trading Filed: 2026-03-17

Key Insights

The CEO, Jamie L. Reynoso, has conducted routine sales of Class A common stock to cover tax obligations associated with the vesting of restricted stock units (RSUs).
The RSUs vest quarterly in equal installments, with the final vesting occurring on September 15, 2026, subject to Reynoso's continued service.
The sales represent a small portion of Reynoso's overall beneficial ownership, which remains significant at over 2.7 million shares of Class A common stock.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information